{"id":59880,"date":"2026-03-18T16:02:19","date_gmt":"2026-03-18T08:02:19","guid":{"rendered":"https:\/\/flcube.com\/?p=59880"},"modified":"2026-03-18T16:02:19","modified_gmt":"2026-03-18T08:02:19","slug":"everest-medicines-signs-loi-to-acquire-haisen-pharmaceutical-rmb-200-million-deposit-for-14-product-apac-commercial-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59880","title":{"rendered":"Everest Medicines Signs LOI to Acquire Haisen Pharmaceutical \u2013 RMB 200 Million Deposit for 14\u2011Product APAC Commercial Platform"},"content":{"rendered":"\n

Everest Medicines Limited<\/strong> (HKG: 1952<\/a>) announced the signing of a letter of intent<\/strong> to acquire Haisen Pharmaceutical (SG) Pte. Ltd.<\/strong> from Hasten Biopharmaceuticals (Asia) Limited<\/strong>, a strategic transaction that would deliver 14 branded chronic disease products<\/strong>, Marketing Authorization Holder (MAH) rights<\/strong>, and an established pan\u2011APAC commercial platform<\/strong> to accelerate Everest’s Asia\u2011Pacific market expansion.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Deal Structure<\/strong><\/td>Letter of Intent (LOI) for 100% equity acquisition<\/td><\/tr>
Target<\/strong><\/td>Haisen Pharmaceutical (SG) Pte. Ltd. (wholly\u2011owned subsidiary of Hasten Biopharmaceuticals Asia)<\/td><\/tr>
Acquirer<\/strong><\/td>Everest Medicines Limited (HKG: 1952)<\/td><\/tr>
Refundable Deposit<\/strong><\/td>RMB 200 million<\/strong> (\u2248\u202fUS$29 million)<\/td><\/tr>
Payment Terms<\/strong><\/td>Within 5 business days of LOI signing; convertible to acquisition consideration or refundable under conditions<\/td><\/tr>
Exclusivity Period<\/strong><\/td>6 months<\/strong> for negotiated transaction completion<\/td><\/tr>
Due Diligence Access<\/strong><\/td>Authorized by Haisen Pharmaceutical (Asia) management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Asset Profile \u2013 Haisen Pharmaceutical (SG)<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Focus Area<\/strong><\/td>Prescription drug commercialization \u2013 chronic and acute care<\/td><\/tr>
Therapeutic Segments<\/strong><\/td>Cardiovascular and metabolic diseases<\/strong> (core); additional chronic disease assets<\/td><\/tr>
Product Portfolio<\/strong><\/td>14 branded products<\/strong> in chronic disease field<\/td><\/tr>
Geographic Rights<\/strong><\/td>Multiple Asia\u2011Pacific countries and regions<\/td><\/tr>
IP & Commercial Rights<\/strong><\/td>MAH rights, trademarks, extensive commercialization rights<\/td><\/tr>
Platform Capability<\/strong><\/td>Pan\u2011APAC commercial infrastructure with value realization track record<\/td><\/tr>
Patient Reach<\/strong><\/td>Tens of millions of chronic disease patients served<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Transaction Drivers<\/h2>\n\n\n\n
Strategic Objective<\/th>Haisen Asset Contribution<\/th>Everest Benefit<\/th><\/tr><\/thead>
Pipeline Enrichment<\/strong><\/td>14 established branded products<\/td>Immediate revenue\u2011generating assets; reduces clinical\u2011stage pipeline risk<\/td><\/tr>
APAC Scale Expansion<\/strong><\/td>Multi\u2011country MAH rights and distribution networks<\/td>Accelerated geographic diversification beyond Greater China<\/td><\/tr>
Asian Market Layout<\/strong><\/td>Established cardiovascular\/metabolic franchise<\/td>Platform for Everest’s innovative drug portfolio launch<\/td><\/tr>
Commercial Infrastructure<\/strong><\/td>Pan\u2011APAC commercial platform with proven execution<\/td>Avoids 3\u20115 year build\u2011out timeline; immediate go\u2011to\u2011market capability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n